Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Abstract Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the Europ...

Full description

Bibliographic Details
Main Authors: Maria H. Gilleece, Avichai Shimoni, Myriam Labopin, Stephen Robinson, Dietrich Beelen, Gerard Socié, Ali Unal, Arnold Ganser, Antonin Vitek, Henrik Sengeloev, Ibrahim Yakoub-Agha, Eleni Tholouli, Emmanuelle Polge, Mohamad Mohty, Arnon Nagler
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00479-3

Internet

https://doi.org/10.1038/s41408-021-00479-3

Similar Items